The Fact About BCAT-IN-4 That No One Is Suggesting
The main end issue was the protection and tolerability of sifalimumab. Procedure-emergent adverse occasions (AEs) and major AEs (SAEs) and their severity, consequence, and any partnership on the examine medication ended up recorded from the investigator through the examine. AEs were being regarded more likely to be associated with review medication